Immunoaugmenting therapeutics

Recombinant cytokines and biological response modifiers

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Immunotherapy has a long history in the treatment of cancer. Immunoaugmenting drugs were popularized by William B. Coley, who treated cancer patients with mixed bacterial toxins early in the 20th century.1 These early studies resulted in the clinical approval of microbially derived substances such as Bacille Calmette-Guerin (BCG) (bladder cancer, USA), Krestin, Picibanil, and Lentinan (gastric and other cancers, Japan), and Biostim and Broncho-Vaxom (recurrent infections, Europe). While these “crude” drugs have numerous immune augmenting activities, they also have regulatory difficulties due to impurities, lot-to-lot variability, and adverse side effects. Similarly, traditional herbal medicines (Asia) may contain constituents with immunotherapeutic activity. The purification, characterization, and synthetic production of active moieties from natural products (Bestatin, Taxol) and culture supernatants (FK-506, Rapamycin, Deoxyspergualin, and Cyclosporin) have provided valuable drugs. The current developmental focus is on recombinant proteins (cytokines and monoclonal antibodies (mAbs)), although the utility of these drugs are limited due, in part, to bioactivity and pharmacologic deficiencies (see chapter 8 of this volume for a discussion of cytokines and monoclonal antibodies as therapeutic agents).

Original languageEnglish (US)
Title of host publicationImmunotoxicology and Immunopharmacology, Third Edition
PublisherCRC Press
Pages143-170
Number of pages28
ISBN (Electronic)9781420005448
ISBN (Print)9780849337901
StatePublished - Jan 1 2006

Fingerprint

Immunologic Factors
Cytokines
Pharmaceutical Preparations
Lentinan
Monoclonal Antibodies
Picibanil
Bacterial Toxins
Herbal Medicine
Traditional Medicine
Tacrolimus
Sirolimus
Therapeutics
Paclitaxel
Biological Products
Recombinant Proteins
Urinary Bladder Neoplasms
Immunotherapy
Cyclosporine
Stomach Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Talmadge, J. E. (2006). Immunoaugmenting therapeutics: Recombinant cytokines and biological response modifiers. In Immunotoxicology and Immunopharmacology, Third Edition (pp. 143-170). CRC Press.

Immunoaugmenting therapeutics : Recombinant cytokines and biological response modifiers. / Talmadge, James E.

Immunotoxicology and Immunopharmacology, Third Edition. CRC Press, 2006. p. 143-170.

Research output: Chapter in Book/Report/Conference proceedingChapter

Talmadge, JE 2006, Immunoaugmenting therapeutics: Recombinant cytokines and biological response modifiers. in Immunotoxicology and Immunopharmacology, Third Edition. CRC Press, pp. 143-170.
Talmadge JE. Immunoaugmenting therapeutics: Recombinant cytokines and biological response modifiers. In Immunotoxicology and Immunopharmacology, Third Edition. CRC Press. 2006. p. 143-170
Talmadge, James E. / Immunoaugmenting therapeutics : Recombinant cytokines and biological response modifiers. Immunotoxicology and Immunopharmacology, Third Edition. CRC Press, 2006. pp. 143-170
@inbook{e1f2015f0c884df6a0e2e50d68f77a30,
title = "Immunoaugmenting therapeutics: Recombinant cytokines and biological response modifiers",
abstract = "Immunotherapy has a long history in the treatment of cancer. Immunoaugmenting drugs were popularized by William B. Coley, who treated cancer patients with mixed bacterial toxins early in the 20th century.1 These early studies resulted in the clinical approval of microbially derived substances such as Bacille Calmette-Guerin (BCG) (bladder cancer, USA), Krestin, Picibanil, and Lentinan (gastric and other cancers, Japan), and Biostim and Broncho-Vaxom (recurrent infections, Europe). While these “crude” drugs have numerous immune augmenting activities, they also have regulatory difficulties due to impurities, lot-to-lot variability, and adverse side effects. Similarly, traditional herbal medicines (Asia) may contain constituents with immunotherapeutic activity. The purification, characterization, and synthetic production of active moieties from natural products (Bestatin, Taxol) and culture supernatants (FK-506, Rapamycin, Deoxyspergualin, and Cyclosporin) have provided valuable drugs. The current developmental focus is on recombinant proteins (cytokines and monoclonal antibodies (mAbs)), although the utility of these drugs are limited due, in part, to bioactivity and pharmacologic deficiencies (see chapter 8 of this volume for a discussion of cytokines and monoclonal antibodies as therapeutic agents).",
author = "Talmadge, {James E}",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780849337901",
pages = "143--170",
booktitle = "Immunotoxicology and Immunopharmacology, Third Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Immunoaugmenting therapeutics

T2 - Recombinant cytokines and biological response modifiers

AU - Talmadge, James E

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Immunotherapy has a long history in the treatment of cancer. Immunoaugmenting drugs were popularized by William B. Coley, who treated cancer patients with mixed bacterial toxins early in the 20th century.1 These early studies resulted in the clinical approval of microbially derived substances such as Bacille Calmette-Guerin (BCG) (bladder cancer, USA), Krestin, Picibanil, and Lentinan (gastric and other cancers, Japan), and Biostim and Broncho-Vaxom (recurrent infections, Europe). While these “crude” drugs have numerous immune augmenting activities, they also have regulatory difficulties due to impurities, lot-to-lot variability, and adverse side effects. Similarly, traditional herbal medicines (Asia) may contain constituents with immunotherapeutic activity. The purification, characterization, and synthetic production of active moieties from natural products (Bestatin, Taxol) and culture supernatants (FK-506, Rapamycin, Deoxyspergualin, and Cyclosporin) have provided valuable drugs. The current developmental focus is on recombinant proteins (cytokines and monoclonal antibodies (mAbs)), although the utility of these drugs are limited due, in part, to bioactivity and pharmacologic deficiencies (see chapter 8 of this volume for a discussion of cytokines and monoclonal antibodies as therapeutic agents).

AB - Immunotherapy has a long history in the treatment of cancer. Immunoaugmenting drugs were popularized by William B. Coley, who treated cancer patients with mixed bacterial toxins early in the 20th century.1 These early studies resulted in the clinical approval of microbially derived substances such as Bacille Calmette-Guerin (BCG) (bladder cancer, USA), Krestin, Picibanil, and Lentinan (gastric and other cancers, Japan), and Biostim and Broncho-Vaxom (recurrent infections, Europe). While these “crude” drugs have numerous immune augmenting activities, they also have regulatory difficulties due to impurities, lot-to-lot variability, and adverse side effects. Similarly, traditional herbal medicines (Asia) may contain constituents with immunotherapeutic activity. The purification, characterization, and synthetic production of active moieties from natural products (Bestatin, Taxol) and culture supernatants (FK-506, Rapamycin, Deoxyspergualin, and Cyclosporin) have provided valuable drugs. The current developmental focus is on recombinant proteins (cytokines and monoclonal antibodies (mAbs)), although the utility of these drugs are limited due, in part, to bioactivity and pharmacologic deficiencies (see chapter 8 of this volume for a discussion of cytokines and monoclonal antibodies as therapeutic agents).

UR - http://www.scopus.com/inward/record.url?scp=85056912328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056912328&partnerID=8YFLogxK

M3 - Chapter

SN - 9780849337901

SP - 143

EP - 170

BT - Immunotoxicology and Immunopharmacology, Third Edition

PB - CRC Press

ER -